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ABSTRACT
Objective To study rates of relapse in remitted patients
with first episode psychosis who either continued or
discontinued antipsychotic drugs after at least one year of
maintenance treatment.
Design 12 month randomised, double blind, placebo
controlled trial.
Setting Early psychosis outpatient clinics in Hong Kong.
Participants 178 patients with first episode psychosis
who had received at least one year of antipsychotic drug
treatment between September 2003 and July 2006 and
had no positive symptoms of psychosis.
Interventions Patients received either maintenance
treatment with quetiapine (400 mg/day) or placebo and
were followed up for the next 12months or until a relapse
occurred.
Main outcome measure Relapse assessed monthly and
defined as re-emergence of psychotic symptoms
(delusions, conceptual disorganisation, hallucinations,
suspiciousness, and unusual thought content) according
to predefined thresholds.
Results 178 patients were randomised (89 to quetiapine
and 89 to placebo). The Kaplan-Meier estimate of the risk
of relapse at 12 months was 41% (95% confidence
interval 29% to 53%) for the quetiapine group and 79%
(68% to 90%) for the placebo group (P<0.001). Although
quetiapine was generally well tolerated, the rate of
discontinuation due to adverse or serious adverse events
was greater in the quetiapine group (18%; 16/89) than in
the placebo group (8%; 7/89) (relative risk 2.29, 95%
confidence interval 0.99 to 5.28; χ2=3.20, df=1; P=0.07).
Conclusion In a group of asymptomatic patients with first
episode psychosis and at least one year of previous
antipsychotic drug treatment, maintenance treatment
with quetiapine compared with placebo resulted in a
substantially lower rate of relapse during the following
year.
Trial registration Clinical trials NCT00334035.
INTRODUCTION
Prevention of relapse is an important target in the treat-
ment of schizophrenia and related psychotic
conditions.1 In first episode psychosis, more than
80% of patients treated achieve a full response in psy-
chotic symptoms,2 yet as many as 80% have a relapse
within five years.3 Relapse compromises the outcome
of psychotic disorders and is associated with substan-
tial risks and costs.4 With each relapse, the response of
symptoms to treatment seems to take approximately
50% longer and is increasingly difficult to re-
establish.5 Prevention of relapse is particularly impor-
tant in the early course of illness, when symptoms and
disabilities may be less entrenched. Strategies to
improve adherence and minimise early relapses are
major focuses in treatment programmes and clinical
research.1 For chronic psychotic illness, maintenance
antipsychotic drug treatment is efficacious for prevent-
ing relapse. The rate of relapse after discontinuation of
drug treatment in chronic schizophrenia is approxi-
mately 53% compared with 16% for patients
maintained on antipsychotic drugs.6 Atypical anti-
psychotic drugs may have some benefits compared
with typical antipsychotics in preventing relapse in
chronic illness.7 8 The biological mechanism underly-
ing relapse is not fully understood; a hyperdopaminer-
gic state resulting from dysregulation and endogenous
sensitisation of the central meso-limbic and meso-cor-
tical dopamine systems have been proposed.9
For patients with first episode psychosis, the few ran-
domised placebo controlled trials of relapse preven-
tion were carried out in patients soon after discharge
from hospital.10-12 Kane et al randomised 30 patients
with at least four weeks of stable remission after admis-
sion to hospital (17 placebo v 13 fluphenazine) and
found that 41% in the placebo group relapsed (defined
as substantial clinical deterioration with marked social
impairment) compared with none in the maintenance
group.11 Crow et al randomised 120 patients within
one month of discharge (66 on placebo v 54 on
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antipsychotics) and found that 62% of the placebo
group and 46% of the maintenance group relapsed
(resumption of drug or readmission to hospital) over
the next 24 months.10 Hogarty et al studied 75 patients
with two months of antipsychotic treatment after dis-
charge from hospital and found that relapse (unequi-
vocal clinical deterioration or imminent readmission)
occurred in 64% of the placebo group and 43% of the
maintenance group.12
Clinical guidelines recommend maintenance drug
treatment for the first year after the onset of illness, but
no consensus exists regarding longer periods ofmainte-
nance treatment.13-16 Some authors estimated that up to
aquarter ofpatientswith first episodepsychosismaynot
need long term maintenance treatment,17 whereas
others question whether it should ever be
discontinued.1618 Two recent studies investigated first
episode patients with somewhat longer periods of
remission. Gitlin et al randomised 108 patients pre-
viously treated with depot fluphenazine for one year to
placebo and maintenance groups (54 each) for three
months, followed by a crossover of treatment in the
next three months, then open label discontinuation.19
Exacerbation was defined as a recurrence of mild psy-
chotic symptoms (a2point change, to a score>3, onany
of three brief psychiatric rating scale psychosis items).
Relapse was defined as a recurrence of severe psychotic
symptoms (a rating of 6 or 7 on any of three brief psy-
chiatric rating scale psychosis items). Unfortunately,
interpretation of the effect of drug treatment was com-
plicated by persistence of the depot fluphenazine in the
placebo group. After open label discontinuation, 78%
had an exacerbation or relapse in the next 12 months.
However, without randomisation and blinding, the
effects of participants’ and raters’ expectations on the
assessments remain uncertain. In another study of
drug discontinuation, Wunderink et al randomised
128 patients who were in remission for six months (65
open withdrawal, 63 open continuation of drug).20 The
study did not involve a placebo control. Relapse (clin-
ical deterioration with one or more score in the severe
range of 5 or more in the positive and negative syn-
drome scale positive subscale21) was more frequent in
the discontinuation group (43%) than in the mainte-
nance treatment group (21%).
In the context of the limited available evidence, dis-
continuation of drug treatment is perceived as a viable
option for patients with first episode psychosis after at
least one year of antipsychotic drug treatment without
relapse.3 22 Longer term maintenance treatment, with
its associated long term side effects,10 is often unaccep-
table to first episode patients.18 Currently, decisions
and guidelines on discontinuation must be made with-
out directly relevant, randomised, placebo controlled
data. In addition, no robust predictors exist to identify
patients at low risk of relapse.23
METHODS
This double blind randomised controlled study aimed
to investigate the effect of discontinuing maintenance
treatment in a group of first episode patients who had
completed at least one year of antipsychotic drug treat-
ment with no relapses. Additionally, to optimise the
clinical relevance of the study and the likelihood of
successful discontinuation, we enrolled only patients
clinically judged to be free of psychotic symptoms for
at least eight weeks. Our primary hypothesis was that
even for this group of patients selected for their good
response, more patients randomised from existing
treatment to placebo (discontinuation) than patients
randomised to maintenance treatment (standardised
to quetiapine) would relapse during one year of fol-
low-up. We investigated readmission to hospital as a
secondary outcome and also did an exploratory analy-
sis of potential predictors of relapse.
Study sites and participants
Psychiatric care for first episode psychosis in Hong
Kong is provided by specialised teams covering the
entire population of approximately seven million.
The Early Assessment Service for Young People with
Psychosis (EASY) evaluatesmore than 600 new cases a
year and provides comprehensive, guideline based
case management for the first three years of illness.24
To enter the EASY programme, patients must have
first episode psychosis, defined by continuously pre-
sent psychotic symptoms since onset, no previous psy-
chotic episodes, and no previous treatment or
remission.
Inclusion criteria for the study included a diagnosis
of schizophrenia or non-affective psychosis (schizo-
phreniform disorder, schizoaffective disorder, brief
psychotic disorder, or psychosis not otherwise speci-
fied) according to the Diagnostic and Statistical Man-
ual for Mental Disorders, fourth edition (DSM-IV).25
Experienced (equivalent to royal college or board cer-
tified) psychiatrists confirmed the diagnosis according
to the Chinese version of the structured clinical inter-
view for DSM-IV.26 In addition, patients had to be
aged 18 to 65, to have received antipsychotic drug
treatment continuously for at least 12 months, and to
have no history of relapse (defined as any increase in
positive symptoms leading to adjustment of drug treat-
ment or readmission to hospital). We ascertained this
with information from patients, carers, case managers,
clinicians, and clinical records. Patients had to be non-
psychotic at study entry, as defined by having below
threshold scores on five key psychotic symptoms on
the positive and negative syndrome scale (table 1), 21
as well as free of positive symptoms of psychosis for at
least eight weeks. Patients also had to score 2 (border-
line or questionable mental illness) or below on the
clinical global impressions scale. 27
Exclusion criteria were drug induced psychosis and
current treatment with clozapine or depot anti-
psychotics or with mood stabilising drugs (lithium,
valproate, or carbamazepine). Other exclusion criteria
included poor adherence to treatment (missing >50%
of drug,>50%non-attendance at follow-up clinic visits,
or a history of patient initiated discontinuation of treat-
ment), and risk of suicide or violence.
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All participants gave written informed consent. All
study participants were monitored by specialised clin-
ical teams, as well as by the research team, and had
access to a dedicated telephone hotline.
Randomisation and blinding
We randomised patients to maintenance with quetia-
pine (400 mg/day) or placebo of identical appearance
for the next 12 months. AstraZeneca generated a ran-
domisation sequence by computer, with a fixed block
size of four without stratification. AstraZeneca pre-
pared individually numbered sets of study drugs,
packed them according to the randomisation
sequence, and then shipped them to the study team in
numbered but apparently identical sets. Study investi-
gators assigned the study drug sets to participants con-
secutively according to the sequence of study entry.
Investigators, patients, and all research staff were
blind to the study drugs and the block size.
Study design
Patients had been treated with several different anti-
psychotic drugs for the 12 months before screening
for entry to the study (table 2).We chose to randomise
patients to a single antipsychotic drug or to placebo for
prevention of relapse. This strategy avoids possible dif-
ferences between subgroups of patients takingdifferent
maintenance drugs. Atypical antipsychotics are
increasingly chosen for maintenance treatment in first
episode psychosis. Among the three atypical anti-
psychotics available in Hong Kong at the time we
started the study, we were able to obtain matching pla-
cebo tablets from the manufacturer only for quetia-
pine. We chose a dose of 400 mg/day on the basis of
the usual effective dose in patients with chronic illness;
this dose has been shown to be efficacious for first epi-
sode patients. 28
We achieved transition to the study drug by cross-
tapering over four to six weeks. We then assessed
patients 12 times in the following year at approxi-
mately monthly intervals or until they had a relapse.
We assessed adherence to treatment by clinical inter-
views with participants and informants, as well as by
pill counting.
Outcome measures
As patients were non-psychotic at entry to the study,
we defined relapse as the reappearance of definite psy-
chotic symptoms (beyond ratings of “questionable” or
“within limits of normal experience”) according to pre-
defined thresholds (table 1), together with a clinical
global impressions score of 3 or above. This approach
is consistent with earlier studies of relapse29; it repre-
sents a categorical shift in illness state. Our definitions
are similar to the “exacerbation” described byGitlin et
al and are more liberal in defining relapse than the
requirement for “substantial” or “unequivocal” dete-
rioration or readmission to hospital used in other
studies. 10-12 19 The lower threshold for defining relapse
allowed recurrence of psychotic symptoms to be
recognised early and appropriate interventions to be
started. We used alternative thresholds for defining
relapse in secondary analyses (see below).Nine trained
clinicians assessed the inter-rater reliability for each of
the positive symptoms by using an independent sam-
ple of 20 patients (weighted κ=0.72-0.92). A secondary
relapse related measure was readmission to hospital.
To assess the functional implications of relapse,
employment status (employed or otherwise) was
reported at baseline and follow-up. Table 3 describes
potential predictor variables for relapse and their mea-
surements.
Side effects and adverse events
We assessed side effects monthly with the Udvalg for
Kliniske Undersøgelser scale.36 We assessed move-
ment disorders with the Barnes akathisia rating
scale,37 the abnormal involuntary movement scale,38
and the Simpson Angus scale.39 We measured body
weight and body mass index at baseline and at six and
12 months. We defined adverse events as adverse
occurrences that may have been related to the drug
and serious adverse events as death, hospital admis-
sion, or persistent incapacity.
Statistical analysis
We estimated statistical power according to Collett
(1994),40 by first determining the required number of
outcome events (relapses). Because some relapses dur-
ing the transition from drug at entry to study drug
could be related to the transition itself, we planned to
ensure that the comparison of post-transition relapses
would have sufficient power. No controlled study data
for this group had been reported in the literature at the
time we were planning the study; naturalistic studies
suggested a range of relapse rates from 30% to 55%.
We aimed to be able to detect an effect that would
Table 1 | Criteria for remission and relapse*
Assessments
Score indicating
remission
Threshold score indicating
relapse
Specific items (PANSS21)†:
P1: Delusions ≤2 3
P2: Conceptual disorganisation ≤3 4
P3: Hallucinatory behaviour ≤2 3
P6: Suspiciousness ≤4 5
G9: Unusual thought content ≤3 4
Global scores (CGI27)‡
Severity of illness ≤2 3
Improvement NA 5
CGI=clinical global impressions; NA=not applicable; PANSS=positive and negative syndrome scale.
*For remission, patients had to meet all specified criteria; for relapse, patients had to meet at least one of
specific item criteria and both of global criteria, for at least one week.
†Scale comprises 30 items, with items specifically related to symptoms of psychosis selected. Each item is
rated 1-7 using anchor statements for each 1 point interval. Scale starts with score of 1, which indicates
absence of symptoms, followed by level(s) describing experiences that are “questionable and within limits of
normal experience,” and then levels indicating definite psychotic symptoms. In several items, a higher rating
level is needed to signify presence of a “psychotic” state. Therefore, the threshold is applied by using relevant
anchor points for each item in scale.
‡Range of possible severity of illness scores: 1 (not mentally ill) to 7 (extremely ill). A score of 2 indicates
borderline or questionable presence of mental illness; 3 indicates a mild level of severity. A score of 5 for
improvement indicates that patient is minimally worse.
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result in a post-transition relapse rate of 45% in the dis-
continuation group and 25% in themaintenance group
(a hazard ratio of 0.48). To detect this effect with a type
I error of 0.05 (two tailed), and a power of 0.8, we
needed a total of at least 58 post-transition relapses.40
We therefore planned to recruit patients until at least
58 post-transition relapses took place. We stopped
recruitment when 60 post-transition relapses had
occurred in the study, after 178 patients had been ran-
domised. Subsequent to our data collection, a rando-
mised open label study of discontinuation versus
maintenance treatment reported relapse rates of 43%
and 21%, giving a hazard ratio of 0.42.20 Our study
would have a power of 0.9 in detecting a similar effect.
We used SPSS software (version 16.0) for the statis-
tical analysis. All tests were two tailed with a signifi-
cance level of P<0.05. We included all completers
(either reaching the end of the study or relapsing) and
all discontinued participants. The primary outcome
measure was reappearance of definite psychotic symp-
toms. The positive and negative syndrome scale scores
of two patients were missing at the point of relapse (as
they were admitted to hospital before the research
team was notified), but in both cases clinical informa-
tion indicated that they were experiencing consider-
able hallucinations and delusions. We assigned both
cases as relapses and treated them as such in the survi-
val analysis.
We calculated the relapse-free survival time from
randomisation to the last visit or relapse. Patients who
discontinued from the study (mostly because of
adverse events) continued to be managed by their
usual clinical teams. Their team physicians decided
whether to continue further maintenance treatment
while remaining blinded to the patients’ study treat-
ments (active or placebo). As this trial specific scenario
would not occur in routine clinical practice, we cen-
sored data from patients who discontinued at the time
of discontinuation in the primary survival analysis.
This approach is acceptable for an explanatory efficacy
study to provide the most meaningful estimate of the
effect of maintenance treatment with the study drug.41
We used the Kaplan-Meier method to construct survi-
val curves and the log-rank test to compare them.
We planned a post-transition subgroup analysis
excluding early relapses (occurring within 60 days of
randomisation, and thus possibly related to switching
medication). Two post hoc sensitivity analyses
assessed the impact of more stringent criteria for
relapse: two or more psychotic symptoms above
threshold, and any psychotic symptom with a score
of 5 (moderately severe) or above. We censored
patients with less severe psychotic symptoms. A sec-
ondary post hoc analysis evaluated the rates of hospital
admission for all causes in the two treatment groups
(Fisher’s exact test for small number of counts). Two
further post hoc sensitivity analyses evaluated the
effects of including estimates for post-discontinuation
data. In the first analysis, we estimated the worst case
scenario by treating all discontinuations as relapses.42
In the second analysis, we made a clinically pragmatic
estimate by using data from case notes about relapses
for the period after discontinuation from the study. In
addition, we categorised patients into four groups on
Table 2 | Baseline drug treatment. Values are numbers (percentages) unless stated otherwise
Characteristics Quetiapine group (n=89) Placebo group (n=89) All patients (n=178)
Median (interquartile range) duration of
antipsychotic treatment before study (days)
647 (472 to 828) 589 (471 to 779) 618 (472 to 784)
Antipsychotic drugs:
Typical antipsychotics 41 (46) 45 (51) 86 (48)
Atypical antipsychotics 48 (54) 44 (49) 92 (52)
Risperidone 14 (16) 22 (25) 36 (20)
Olanzapine 13 (15) 14 (16) 27 (15)
Quetiapine 14 (16) 3 (3) 17 (10)
Amisulpride 7 (8) 4 (4) 11 (6)
Ziprasidone 0 1 (1) 1 (1)
Mean (SD) doses (mg/day):
Typical antipsychotics* 153.0 (193.9) 125.8 (92.3) 138.8 (149.3)
Atypical antipsychotics
Risperidone (n=36) 2.1 (1.3) 2.0 (1.1) 2.1 (1.2)
Olanzapine (n=27) 5.8 (4.8) 7.1 (3.4) 6.5 (4.1)
Quetiapine (n=17) 271.4 (184.7) 140.0 (138.9) 248.2 (181.1)
Amisulpride (n=11) 264.3 (102.9) 200.0 (81.7) 240.9 (97.0)
Ziprasidone (n=1) NA 40 40
Concurrent drugs:
Antidepressants 20 (22) 16 (18) 36 (20)
Anticholinergics 11 (12) 10 (11) 21 (12)
Benzodiazepines 3 (3) 4 (4) 7 (4)
NA=not applicable.
*Daily dosage reported in form of chlorpromazine equivalents in mg.
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the basis of changes in their occupational functioning:
from employed to unemployed, from unemployed to
employed, employed with no change, and unem-
ployed with no change. We used χ2 tests to compare
the proportion of participants with these changes
between the two treatment groups.
We compared discontinuations due to all causes and
those due to adverse events and serious adverse events
by using relative risk and χ2 tests. We compared side
effects at baseline and at follow-up by using χ2 tests or
Fisher’s exact test if the number of side effects in a
group was less than five. We compared body weight
and body mass index between the maintenance and
placebo groups by using t tests both at baseline and at
the end of the study. We used χ2 tests to compare the
proportions of participants with bodymass index of 23
or above and with weight gain of 7% or more between
the two groups. Lastly, we further compared changes
in weight or body mass index between the two groups
by linear regression analysis, with the change as the
dependent variable, the treatment group denoted by
an indicator, and adjustment by weight or body mass
index at baseline by group and previous drug type
(typical or atypical). We validated the fitted models
by diagnostic residual plots.
We used univariate Cox proportional hazards mod-
els to analyse the potential predictors of relapse. We
included variables with P≤0.1 in a multivariate Cox
regression analysis with forward selection. We
assessed the proportional hazard assumption by the
method described in Lin et al,43 using SAS 9.1.3. We
checked associations between the predictors by using
Pearson correlation (continuous variables), χ2 test
(categorical variables), or Wilcoxon rank sum test
(continuous and categorical variables). We re-fitted
the selectedCoxmodel to all patientswith non-missing
predictors to obtain more precise estimates. We calcu-
lated relative risk as the ratio between the outcome
(relapse) rate in the population exposed to the risk fac-
tor (placebo) divided by the outcome rate in the popu-
lation not exposed to the risk factor (maintenance
quetiapine).
RESULTS
Study population
Between September 2003 and July 2006, we assessed
consecutive patients already enrolled in the early psy-
chosis programme for eligibility to participate in the
relapse prevention study. We screened 1606 patients
for eligibility (fig 1). Schizophrenia was the most com-
mon diagnosis in enrolled patients (table 4). Before
randomisation, patients had received antipsychotic
drugs for a median of 21 months (618 (interquartile
range 472-784) days) (table 2). The total symptom
severity scores were low, and the median global sever-
ity of illness rating was 1, or “not mentally ill.” The
level of functioning as assessed by the rating scales
and proportion employed was moderately high. Base-
line variables in the group randomised to quetiapine
did not differ from those randomised to placebo (all
P>0.05). Including patients who completed the study,
relapsed, or were withdrawn, the median duration of
follow-up was 145 (41-351) days for the quetiapine
group and 106 (57-243) days for the placebo group.
Table 3 | Predictors of relapse in univariate and multivariate Cox proportional hazards regression analysis (n=178)
Predictors
Univariate analysis* Multivariate analysis (n=160)
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Treatment (quetiapine or placebo) 0.41 (0.26 to 0.65) <0.001 0.37 (0.23 to 0.60) <0.001
Schizophrenia diagnosis† 1.83 (1.18 to 2.85) 0.01 1.72 (1.07 to 2.76) 0.03
PSST,32 1 unit (n=160) 1.87 (1.16 to 3.02) 0.01 1.86 (1.15 to 3.00) 0.01
SOFAS,30‡ 1 unit 0.98 (0.96 to 0.99) 0.01 0.98 (0.96 to 1.00) 0.05
Sex 1.11 (0.72 to 1.71) 0.64 NA
Age of onset, year 1.00 (0.97 to 1.03) 0.84 NA
Age, year 1.00 (0.97 to 1.03) 0.99 NA
Education, year 0.95 (0.89 to 1.02) 0.18 NA
SANS,33 1 unit 1.01 (1.00 to 1.03) 0.05 NA
SAPS,34 1 unit 0.87 (0.67 to 1.12) 0.28 NA
SUMD,35 1 unit (n=159) 1.10 (0.98 to 1.24) 0.09 NA
PAS,31§ 1 unit (n=157) 1.24 (0.98 to 1.58) 0.08 NA
Concomitant treatment 1.53 (0.96 to 2.43) 0.08 NA
Duration of untreated psychosis, day 1.00 (1.00 to 1.00) 0.51 NA
Duration of previous antipsychotic treatment, day 1.00 (1.00 to 1.00) 0.25 NA
Type of previous antipsychotic treatment (atypical or typical) 0.84 (0.55 to 1.31) 0.45 NA
NA=not applicable; PAS=premorbid adjustment scale (range 10-70); PSST=assessment of premorbid schizoid-schizotypal traits; SANS=scale for the assessment of negative symptoms (range
0-120); SAPS=scale for the assessment of positive symptoms (range 0-175); SOFAS=social and occupational functioning assessment scale (range 1-100); SUMD=scale to assess
unawareness of mental disorder (range 3-9).
*For continuous variables, hazard ratio represents relative increase in hazard with one unit increment in variable. Predictors with significance level at <0.1 (df=1) in univariate analysis were
included in multivariate analysis.
†Categorised into schizophrenia and non-schizophrenia (including schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, and psychosis not otherwise specified).
Schizophrenia diagnosis was correlated with SANS (z=−4.122; P<0.001).
‡SOFAS was correlated with SANS (r=–0.59; P<0.001) and schizophrenia diagnosis (z=−2.45; P=0.01).
§PAS was correlated with PSST (r=0.54; P<0.001), SANS (r=0.18; P=0.02) and SOFAS (r=–0.17; P=0.03).
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Primary outcome: relapse
Twenty-seven of 89 patients relapsed in the quetiapine
group, and 56 of 89 patients relapsed in the placebo
group. The Kaplan-Meier estimate of the proportion
relapsed at 12 months was 41% (95% confidence inter-
val 29% to 53%) in the quetiapine group and 79% (68%
to 90%) in the placebo group (χ2=15.65, df=1; P<0.001
by log-rank) (fig 2). In the post-transition subgroup
analysis excluding the 23 patients who relapsed within
60 days, fewer patients in the quetiapine group
relapsed (22% (17/79); 12 month Kaplan-Meier esti-
mate 32%, 19% to 45%) than in the placebo group
(57% (43/76); 75%, 62% to 89%) (χ2=19.17, df=1;
P<0.001 by log-rank).
In relapses, specific symptoms that scored at or
above the threshold included delusions (72%; 58/81),
hallucinations (54%; 44/81), suspiciousness (38%; 31/
81), conceptual disorganisation (30%; 24/81), and unu-
sual thought content (23%; 19/81); 68% (55/81) of
patients had two or more types of psychotic symptom.
The most common co-occurring psychotic symptoms
were delusions and hallucinations (37%; 30/81) and
delusions and suspiciousness (31%; 25/81). The mag-
nitude of the highest score of the five key symptoms
defining relapse did not differ between relapsing
patients in the two treatment groups (mean (SD) 4.30
(0.91) in quetiapine group (n=27) v 4.50 (0.82) in pla-
cebo group (n=54); t=−1.02, df=79; P=0.31). Nor did
we find a difference in the magnitude of the change in
score from baseline for these symptoms (mean (SD)
3.22 (1.01) in quetiapine group v 3.46 (0.82) in placebo
group; t=−1.15, df=79; P=0.25). We found no
significant correlation between severity of symptoms
at relapse and the time to receiving treatment (r=
−0.37, P=0.06 for quetiapine group; r=0.07, P=0.61
for placebo group).
We did two sensitivity analyses defining relapsewith
more stringent criteria: two or more psychotic symp-
toms above the threshold, and requiring a score of 5
(moderately severe) to define relapse. We censored
patients with less severe psychotic symptoms. When
we used the first criterion, the quetiapine group
showed a significantly lower relapse rate (30%, 95%
confidence interval 18% to 42%) than did the placebo
group (68%, 56% to 80%) (χ2=14.67, df=1; P<0.001 by
log-rank).Whenwe used the second criterion, the que-
tiapine group also showed a significantly lower relapse
rate (27%, 15% to 39%) than did the placebo group
(63%, 46% to 79%) (χ2=11.81, df=1; P=0.001 by log-
rank).
In the post hoc sensitivity analysis of the worst case
scenario, we treated all discontinuations/dropouts as
having relapsed at point of discontinuation. The
Kaplan-Meier estimate of the proportion of relapse at
12 months was 62% (51% to 72%) in the quetiapine
group and 85% (76% to 93%) in the placebo group
(χ2=5.59, df=1; P=0.018 by log-rank). We did another
post hoc sensitivity analysiswith information fromcase
notes about relapses for the post-discontinuation per-
iod. This provides a pragmatic estimate by including
all clinically significant relapses in the post-disconti-
nuation period. TheKaplan-Meier estimate of the pro-
portion of relapse at 12 months was 41% (30% to 51%)
in the quetiapine group and 69% (59% to 79%) in the
placebo group (χ2=14.25, df=1; P<0.001 by log-rank).
Secondary outcome measures
Readmission to hospital was more common in the pla-
cebo group (16% (14/89); 12 relapse, 2 serious adverse
Included in ITT analysis (n=89, 100%):
  Post-transition analysis (n=76, 85%)
  Early relapse (n=13, 15%)
Excluded (n=0, 0%)
Included in ITT analysis (n=89, 100%):
  Post-transition analysis (n=79, 89%)
  Early relapse (n=10, 11%)
Excluded (n=0, 0%)
Assessed for eligibility (n=1606)
Randomised (n=178, 11%)
Completed (n=71, 80%):
  No relapse (n=15, 17%)
  Relapse (n=56, 63%)
Discontinued (n=18, 20%):
  Adverse event (n=6, 7%)
  Serious adverse event (n=1, 1%)
  Withdrew consent (n=6, 7%)
  Other reasons (n=5, 6%)
Lost to follow-up (n=0, 0%)
Completed (n=61, 69%):
  No relapse (n=34, 38%)
  Relapse (n=27, 30%)
Discontinued (n=28, 31%):
  Adverse event (n=15, 17%)
  Serious adverse event (n=1, 1%)
  Withdrew consent (n=6, 7%)
  Other reasons (n=6, 7%)
Lost to follow-up (n=0, 0%)
Assigned to placebo (n=89)
Received placebo (n=89)
Assigned to quetiapine (n=89)
Received quetiapine (n=89)
Excluded (n=1428, 89%):
  Did not meet inclusion criteria (n=1134, 71%):
    Different diagnosis (n=384, 24%)
    Had relapsed (n=332, 21%)
    Active psychosis (n=284, 18%)
    Non-adherent (n=96, 6%)
    Suicidal/other risk (n=38, 2%)
  Refused to participate (n=294, 18%)
Fig 1 | Enrolment and outcomes. ITT=intention to treat
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Fig 2 | Kaplan-Meier analysis in remitted first episode
psychosis patients with and without antipsychotic
maintenance treatment. Median duration of follow-up was
145 (interquartile range 41-351) days for quetiapine group
and 106 (57-243) days for placebo group
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events) than in the quetiapine group (6% (5/89); 4
relapse, 1 serious adverse event) (Fisher’s exact test
(two tailed) P<0.05). The groups did not differ in base-
line occupational status—open employment: quetia-
pine group 70% (62/89); placebo group 73% (65/89).
Some participants lost open employment status in the
study period—quetiapine group 27% (17/62); placebo
group 32% (21/65). Changes in occupational status
(from employed to unemployed, from unemployed
to employed, employed with no change, or unem-
ployed with no change) during the study did not differ
statistically between the two treatment groups
(χ2=1.52, df=3; P=0.68).
Predictors of relapse
We studied predetermined potential predictors of
relapse initially with a univariate Cox regression
model. We then entered variables with P values of 0.1
or below into amultivariate Cox regression.We found
the assumption of proportionality to be valid. Signifi-
cant independent predictors of relapse were mainte-
nance treatment, pre-morbid schizoid and schizotypal
traits, functioning, and diagnosis of schizophrenia
(table 3).
Side effects, adverse events, and discontinuations
Patients taking quetiapine reported more side effects
(sleepiness or sedation, reduced salivation, and consti-
pation) than did those taking placebo (table 5). Only
11% (20/178; 9 in quetiapine group and 11 in placebo
group) of patients had a Simpson Angus scale score
above zero at baseline. Those previously treated with
typical antipsychotics had higher mean scores
(P=0.02). Most (145/168; 76 in quetiapine group and
69 in placebo group) had no change in these scores
during the study. Five had a higher score (four in pla-
cebo group, one in quetiapine group), and 18 had
lower scores (nine in each group). We found no differ-
ence in the change in scores between the two groups.
Only two participants had positive abnormal involun-
tary movement scale scores at baseline (one in quetia-
pine group, one in placebo group); both scores
decreased during the study. Two other patients in the
placebo group (one previously treated with a typical
antipsychotic and one with an atypical antipsychotic)
had an increase in this score during the study. Four
patients had positive scores for akathisia at baseline
(all in placebo group), and six had positive scores at
follow-up (four in quetiapine group, two in placebo
group). Six patients had an increased score (four in
quetiapine group, two in placebo group), and four
had a reduced score at follow-up (all in placebo group).
Table 6 shows changes in body weight and body
mass index; it also shows some summary statistics by
subsets. We found an overall trend for weight reduc-
tion, which was greater in the placebo group (mean
(SD) −3.08 (8.22) kg) than in the quetiapine group
(−0.75 (4.65) kg) (P=0.02). Baseline weight had a signif-
icant effect on the change in weight for the placebo
group; heavier patients at baseline had more weight
reduction (unstandardised regression coefficient
−0.19, 95% confidence interval −0.28 to −0.10;
P<0.001). The baseline effect was not significant for
the quetiapine group (regression coefficient −0.08,
−0.17 to 0.2; P=0.11). Previous drug type had a minor
effect on weight change (typical antipsychotic 1.72
(−0.15 to 3.59) kg more than atypical antipsychotic;
P=0.07). Weight change over time did not differ
between the groups after adjustment forweight at base-
line (placebo group 5.39 (−3.22 to 14.0) kg more than
quetiapine group; P=0.22). The body mass index at
baseline had a significant effect on the change in body
mass index for the placebo group (regression coeffi-
cient −0.25, −0.35 to −0.15; P<0.001) but not for the
quetiapine group (regression coefficient −0.06, −0.16
to 0.40; P=0.26). Previous drug type had no significant
effect on body mass index (typical antipsychotic 0.57
(−0.12 to 1.26) kg more than atypical; P=0.11), but the
mean change in body mass index differed somewhat
between the groups (placebo group 3.74 (0.17 to
7.31) kg more than quetiapine group; P=0.04) after
adjustment for body mass index at baseline. No dia-
betes or ketoacidosis emerged during the study period.
Figure 1 gives reasons for discontinuation. Adverse
events that occurred in more than one case were fati-
gue, sedation, or tiredness (n=9; 7 in quetiapine group,
Table 4 | Baseline characteristics of patients. Values are numbers (percentages) unless stated
otherwise
Characteristics
Quetiapine group
(n=89)
Placebo group
(n=89) All patients (n=178)
Mean (SD) age (years) 23.5 (5.2) 24.9 (7.3) 24.2 (6.4)
Mean (SD) age at onset (years) 21.4 (5.3) 22.4 (7.5) 21.9 (6.5)
Male sex 39 (44) 41 (46) 80 (45)
Mean (SD) education (years) 12.0 (2.6) 11.7 (3.1) 11.8 (2.8)
Employed 62 (70) 65 (73) 127 (71)
Type of disorder:
Schizophrenia 46 (52) 45 (51) 91 (51)
Schizophreniform disorder 15 (17) 12 (13) 27 (15)
Schizoaffective disorder 3 (3) 6 (7) 9 (5)
Brief psychotic disorder 13 (15) 8 (9) 21 (12)
Psychosis not otherwise specified 12 (13) 18 (20) 30 (17)
Comorbid diagnoses:
Affective disorder 5 (6) 2 (2) 7 (4)
Previous substance abuse 2 (2) 4 (4) 6 (3)
Personality disorder 0 1 (1) 1 (1)
Others 1 (1) 0 1 (1)
Mean (SD) PANSS21 sum score (n=177):
Total 36.1 (4.6) 37.1 (6.4) 36.6 (5.6)
Positive 7.2 (0.6) 7.3 (0.7) 7.2 (0.6)
Negative 8.7 (2.9) 9.1 (3.6) 8.9 (3.3)
Mean (SD) CGI27 severity score (n=176) 1.1 (0.3) 1.2 (0.4) 1.1 (0.3)
Mean (SD) SOFAS30 score* 76.4 (10.0) 74.6 (11.7) 75.5 (10.9)
Mean (SD) PAS31† (n=157) 2.7 (0.9) 2.8 (0.8) 2.8 (0.9)
Mean (SD) PSST32‡ (n=160) 1.5 (0.5) 1.5 (0.4) 1.5 (0.5)
CGI=clinical global impressions; PANSS=positive and negative syndrome scale; PAS=premorbid adjustment
scale; PSST=assessment of premorbid schizoid and schizotypal traits; SOFAS=social and occupational
functioning assessment scale.
*Range of scores from 1 to 100, with lower scores representing impaired functioning.
†Measures functional level before onset of illness, with range of scores from 10 to 70 and lower scores
indicating better functioning.
‡Measures premorbid personality in patients before first episode psychosis on basis of interview of an
informant, with range of scores from 8 to 32 and lower scores indicating fewer schizoid-schizotypal traits.
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2 in placebo group), dizziness (n=7; all in quetiapine
group), nausea (n=2; both in quetiapine group), limb
weakness (n=2; both in quetiapine group), and insom-
nia (n=2; 1 in quetiapine group, 1 in placebo group).
Three serious adverse events occurred. One patient
taking quetiapine was admitted to hospital after impul-
sive self-laceration following an argument with a part-
ner, and one assigned to placebo was admitted after a
non-fatal overdose of hypnotics during an adjustment
reaction to financial difficulties. Both were discontin-
ued. A third patient in the placebo group had transient
repetitive imagery for three days and was briefly
admitted for observation, but continued. The rate of
discontinuation for both adverse events and serious
adverse events was higher for the quetiapine group
(18%; 16/89) than the placebo group (8%; 7/89) (rela-
tive risk 2.29, 95% confidence interval 0.99 to 5.28;
χ2=3.20, df=1; P=0.07).
Other reasons for discontinuation included need for
a mood stabiliser (n=3; 2 in quetiapine group, 1 in pla-
cebo group), inability to tolerate the transitionprotocol
(n=7; 4 in quetiapine group, 3 in placebo group), and
unwillingness to attend the study assessments (n=1; in
placebo group). Discontinuation for all causes did not
differ significantly between the quetiapine group (31%;
28/89) and the placebo group (20%; 18/89) (relative
risk 1.32, 0.98 to 1.77; χ2=2.38, df=1; P=0.12).
DISCUSSION
In patients with first episode psychosis, antipsychotic
treatment is often discontinued after one year of good
response. We investigated patients selected from a
representative, population based sample. This group
of patients represents those with the best chance of suc-
cessful discontinuation of treatment.We found amuch
higher rate of relapse in patients randomised to pla-
cebo (79%) than in those receiving active maintenance
treatment (41%). A subgroup analysis excluding
patients with early relapse (possibly related to transi-
tion to the study drug), sensitivity analyses, and com-
parison of rates of admission to hospital were all
consistent with the primary outcome analysis.
Comparison with other studies
The rate of relapse in the placebo group in our study is
higher than in some studies,10 12 but it is lower than in
others.11 19 The relapse rate in themaintenance group is
comparable to that in previous studies.10 12 Our defini-
tion of relapse signified the re-emergence of psychotic
symptoms in patients who were not psychotic at base-
line, consistent with the approach of Vaughn et al.29
This definition of relapse is relevant to real life deci-
sions about treatment, asmost clinicians would recom-
mend resumption of antipsychotic treatment in this
situation. As in other studies with intensive follow-up
and monitoring,19 20 relapses were detected relatively
Table 5 | Side effects reported at baseline and during study period. Values are numbers (percentages) of patients (n=178)
Side effects
Baseline Study period
Quetiapine
group (n=89)
Placebo group
(n=89) P value*
Quetiapine
group (n=89)
Placebo group
(n=89) P value*
UKU36†:
Concentration difficulties 9 (10) 23 (26) 0.01 37 (42) 47 (53) 0.18
Asthenia, lassitude, or
increased fatigability
19 (21) 24 (27) 0.48 52 (58) 46 (52) 0.45
Sleepiness or sedation 23 (26) 19 (21) 0.60 62 (70) 44 (49) 0.01
Failing memory 7 (8) 14 (16) 0.16 33 (37) 30 (34) 0.75
Depression 1 (1) 1 (1) >0.99 16 (18) 12 (13) 0.54
Tension or inner unrest 2 (2) 1 (1) >0.99 19 (21) 14 (16) 0.44
Increased duration of sleep 10 (11) 13 (15) 0.66 45 (51) 35 (39) 0.18
Reduced duration of sleep 1 (1) 1 (1) >0.99 22 (25) 30 (34) 0.25
Tremor 4 (4) 4 (4) >0.99 16 (18) 13 (15) 0.69
Reduced salivation 1 (1) 0 >0.99 13 (15) 4 (4) 0.04
Constipation 2 (2) 0 0.50 13 (15) 4 (4) 0.04
Weight gain 22 (25) 19 (21) 0.72 35 (39) 30 (34) 0.54
Weight loss 0 1 (1) >0.99 9 (10) 23 (26) 0.01
Amenorrhoea 6/50 (12) 5/48 (10) 0.77 12/50 (24) 11/48 (23) >0.99
Headache 4 (4) 2 (2) 0.68 19 (21) 16 (18) 0.71
Akathisia (BARS37)‡ 0 0 >0.99 1 (1) 0 >0.99
Dyskinesia (AIMS38)§ 0 0 >0.99 0 1 (1) 0.48
Parkinsonism (SAS39)¶ 0 0 >0.99 0 1 (1) >0.99
AIMS=abnormal involuntary movement scale; BARS=Barnes akathisia rating scale; SAS=Simpson Angus scale; UKU=Udvalg for Kliniske Undersøgelser
scale.
*Based on χ2 comparisons between quetiapine and placebo groups, or Fisher’s exact test when number of side effects in group is <5.
†Side effects scored as 1 (mild) or higher at baseline or at any time during the study period; extrapyramidal side effects were as defined in CATIE
study,44 with thresholds adjusted for first episode patients.
‡BARS global clinical assessment score ≥2, indicating akathisia of mild or greater severity.
§AIMS global severity score ≥2, indicating abnormal involuntary movements of mild or greater severity.
¶SAS mean score ≥1, indicating extrapyramidal signs of moderate severity.
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early, in most cases before pronounced deterioration
and need for hospital admission. The level of severity
of symptoms thatwe used to define relapse is described
in someother studies as an “exacerbation.”19However,
the relapses into psychosis in our study were not trivial
and in most cases involved two or more types of psy-
chotic symptoms. Predictors of relapse included pre-
morbid schizoid and schizotypal traits and low
psychosocial functioning, as in earlier studies.10 11
Importantly, we found that relapse was related neither
to the type (atypical or typical) nor to the duration of
previous antipsychotic treatment.
Limitations of study
The study has several limitations. The choice of a
design with a standardised drug treatment and a pla-
cebo control required switching of drugs. This design,
however, has the advantages of randomisation and a
double blind placebo control. Without a double blind
control, the effects of patients’ and clinicians’ expecta-
tions cannot be assessed and themagnitude of the ben-
efits of maintenance cannot be quantified. We
evaluated the effects of switching by a subgroup analy-
sis that excluded patients who relapsed within two
months of the switch period. The 12 month Kaplan-
Meier estimate of a 41% relapse rate in the primary
analysis included patients who might have relapsed
as a result of switching in itself. The post-transition sub-
group analysis, which excluded patients who relapsed
early, resulted in a lower 32% relapse rate.
Although the study focused on the impact of anti-
psychotic maintenance on relapse, psychosocial fac-
tors such as expressed emotion also contribute to the
risk of relapse.45 These factors must also be taken into
consideration in clinical decision making for the indi-
vidual patient. Use of illicit substances could also
increase the risk of relapse. However, as the overall
prevalence of substance misuse is much lower in
Hong Kong than in some other populations,46 we did
not do regular laboratory monitoring of illicit sub-
stance use. Finally, although quetiapine seems to be
as effective as other antipsychotic drugs in the treat-
ment of first episode psychosis,47 48 our design does
not consider the question of the relative advantages
or disadvantages of quetiapine compared with other
antipsychotics as a maintenance treatment. Other anti-
psychotics could have different efficacies. Other atypi-
cal antipsychotics could be equally effective at a
different cost, depending on regional pricing and avail-
ability of generic drugs. As a final consideration, this
study specifically targeted a cohort of patients likely to
have a better outcome, and for whom discontinuation
of treatment was a realistic consideration. Althoughwe
did not recruit patients with residual psychotic symp-
toms, or those who already had at least one relapse,
discontinuation in these patientswould probably result
in an even higher risk of relapse than found in this
study. The low rate of substance misuse and high rate
of employment in this group also need to be taken into
consideration before generalising the findings to other
settings.
Conclusion and implications
In summary, even patients with good response in posi-
tive symptoms and good functioning after a first epi-
sode of psychosis have a high risk of relapse, but this
can be reduced with maintenance drug treatment. On
the other hand, maintenance treatment with atypical
antipsychotic drugs is still associated with appreciable
side effects (table 5). This result highlights the chal-
lenges confronting clinicians and patients considering
discontinuation of treatment after a single psychotic
episode. These data provide a strong case for continua-
tion ofmaintenance treatment to beyondone year after
Table 6 | Weight and body mass index (BMI) at baseline and changes during study period*
Quetiapine group
(n=89)
Placebo group
(n=89) df P value
All participants
Mean (SD) weight (kg):
Baseline 66.03 (14.47) 66.28 (15.10) 176 0.91
End of study 65.28 (14.14) 63.36 (14.32) 175 0.37
Mean (SD) BMI:
Baseline 24.46 (4.75) 24.49 (4.95) 176 0.97
End of study 24.19 (4.75) 23.41 (4.64) 175 0.27
No (%) BMI ≥23:
Baseline 49 (55) 53 (60) 1 0.65
End of study 44 (49) 39 (44) 1 0.60
No (%) weight gain ≥7% 9 (10) 9 (10) 1 >0.99
Mean (SD) weight change (kg) −0.75 (4.65) −3.08 (8.22) NA
Mean (SD) BMI change −0.26 (1.72) −1.14 (3.09) NA
BMI <23 at baseline (n=40) (n=35)
Mean (SD) weight change (kg) −0.01 (2.99) −0.83 (5.02) NA
Mean (SD) BMI change −0.002 (1.12) −0.32 (1.79) NA
No (%) BMI ≥23 at end of study 3 (8) 1 (3) NA
BMI ≥23 at baseline (n=49) (n=53)
Mean (SD) weight change (kg) −1.36 (5.62) −4.56 (9.54) NA
Mean (SD) BMI change −0.48 (2.07) −1.68 (3.62) NA
No (%) BMI <23 at end of study 8 (16) 15 (28) NA
Previous typical antipsychotics (n=41) (n=44)
Mean (SD) weight change (kg) −0.21 (5.25) −1.53 (6.92) NA
Mean (SD) BMI change −0.07 (1.92) −0.57 (2.57) NA
Previous atypical
antipsychotics
(n=48) (n=44)
Mean (SD) weight change (kg) −1.22 (4.07) −4.62 (9.16) NA
Mean (SD) BMI change −0.43 (1.53) −1.71 (3.64) NA
NA=not applicable.
WHAT IS ALREADY KNOWN ON THIS TOPIC
After first episode psychosis, the decision on whether to discontinue antipsychotic drugs
after a period of maintenance treatment is a common clinical problem
Little empirical evidence exists to guide physicians in this decision
WHAT THIS STUDY ADDS
Among first episode patients who have had a full remission and taken antipsychotic drugs for
at least a year, the relapse rate after discontinuation was still high compared with those who
continued treatment
These findings are decisive in supporting maintenance treatment, even after one year of
maintenance and in patients with no positive symptoms of psychosis
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a first episode of psychosis, but we also acknowledge
that the clinical decision for maintenance treatment
must be made in an individualised manner taking
into consideration factors such as side effects and the
availability of effective monitoring for relapse. Cur-
rently identified predictors of relapse are still relatively
non-specific, and further research is needed to inform
decisions on maintenance or discontinuation for indi-
vidual patients.
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